Genfit SA Stock Shows Every Sign Of Being Possible Value Trap
- By GF Value
The stock of Genfit SA (NAS:GNFT, 30-year Financials) shows every sign of being possible value trap, according to GuruFocus Value calculation. GuruFocus Value is GuruFocus' estimate of the fair value at which the stock should be traded. It is calculated based on the historical multiples that the stock has traded at, the past business growth and analyst estimates of future business performance. If the price of a stock is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher. At its current price of $4.24 per share and the market cap of $194 million, Genfit SA stock gives every indication of being possible value trap. GF Value for Genfit SA is shown in the chart below.
The reason we think that Genfit SA stock might be a value trap is because its Piotroski F-score is only 1, out of the total of 9. Such a low Piotroski F-score indicates the company is getting worse in multiple aspects in the areas of profitability, funding and efficiency. In this case, investors should look beyond the low valuation of the company and make sure it has no long-term risks. To learn more about how the Piotroski F-score measures the business trend of a company, please go here. Furthermore, Genfit SA has an Altman Z-score of -2.96, which indicates that the financial condition of the company is in the distressed zone and implies a higher risk of bankruptcy. An Altman Z-score of above 2.99 would be better, indicating safe financial conditions. To learn more about how the Z-score measures the financial risk of the company, please go here.
Link: These companies may deliever higher future returns at reduced risk.
Since investing in companies with low financial strength could result in permanent capital loss, investors must carefully review a company's financial strength before deciding whether to buy shares. Looking at the cash-to-debt ratio and interest coverage can give a good initial perspective on the company's financial strength. Genfit SA has a cash-to-debt ratio of 0.92, which ranks worse than 84% of the companies in Biotechnology industry. Based on this, GuruFocus ranks Genfit SA's financial strength as 2 out of 10, suggesting poor balance sheet. This is the debt and cash of Genfit SA over the past years:
Companies that have been consistently profitable over the long term offer less risk for investors who may want to purchase shares. Higher profit margins usually dictate a better investment compared to a company with lower profit margins. Genfit SA has been profitable 0 over the past 10 years. Over the past twelve months, the company had a revenue of $0.9 million and loss of $3.04 a share. Its operating margin is -10131.90%, which ranks in the bottom 10% of the companies in Biotechnology industry. Overall, the profitability of Genfit SA is ranked 2 out of 10, which indicates poor profitability. This is the revenue and net income of Genfit SA over the past years:
One of the most important factors in the valuation of a company is growth. Long-term stock performance is closely correlated with growth according to GuruFocus research. Companies that grow faster create more value for shareholders, especially if that growth is profitable. The average annual revenue growth of Genfit SA is 71%, which ranks better than 90% of the companies in Biotechnology industry. The 3-year average EBITDA growth is -7.6%, which ranks worse than 69% of the companies in Biotechnology industry.
Another way to look at the profitability of a company is to compare its return on invested capital and the weighted cost of capital. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business. The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. We want to have the return on invested capital higher than the weighted cost of capital. For the past 12 months, Genfit SA's return on invested capital is -330.87, and its cost of capital is 6.14.
To conclude, Genfit SA (NAS:GNFT, 30-year Financials) stock shows every sign of being possible value trap. The company's financial condition is poor and its profitability is poor. Its growth ranks worse than 69% of the companies in Biotechnology industry. To learn more about Genfit SA stock, you can check out its 30-year Financials here.
To find out the high quality companies that may deliever above average returns, please check out GuruFocus High Quality Low Capex Screener.
This article first appeared on GuruFocus.
